The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Ute Grabowsky/Photothek via Getty The FDA conducted two studies, both of which found that Zepbound helps reduce sleep apnea symptoms in some patients by aiding weight loss. Both studies monitored ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.